Media ReleasesImugene Limited

View All Imugene Limited News


Imugene Announces New HER-Vaxx Cancer Vaccine Phase Ib trial data to be presented at the American Society of Clinical Oncology 2019 Annual Meeting

SYDNEY, Australia, 29 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced updated data from the ongoing patients in the Phase Ib study of its HER-Vaxx cancer vaccine will be presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois, USA 31 May to 3 June 2019.

The abstract (number 4030) will be presented by Dr Yee Chao, Director of the Department of Oncology at the Veterans General Hospital in Taipei, Taiwan and a lead investigator in the Phase 1b study.

Dr Chao’s presentation will be featured at the ASCO Gastrointestinal (Noncolorectal) Cancer Session on Monday 3 June between 8:00am and 11:00am.


For further information please download PDF attached:
Download this document